NO975703L - Alkylaminderivater av substituerte kinoksalin-2,3-dioner som glutamatreseptor-antagonister - Google Patents

Alkylaminderivater av substituerte kinoksalin-2,3-dioner som glutamatreseptor-antagonister

Info

Publication number
NO975703L
NO975703L NO975703A NO975703A NO975703L NO 975703 L NO975703 L NO 975703L NO 975703 A NO975703 A NO 975703A NO 975703 A NO975703 A NO 975703A NO 975703 L NO975703 L NO 975703L
Authority
NO
Norway
Prior art keywords
substituted quinoxaline
dione
receptor antagonists
glutamate receptor
alkylamine derivatives
Prior art date
Application number
NO975703A
Other languages
English (en)
Other versions
NO309088B1 (no
NO975703D0 (no
Inventor
Brian Edward Kornberg
Sham Shridhar Nikam
Michael Francis Rafferty
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO975703D0 publication Critical patent/NO975703D0/no
Publication of NO975703L publication Critical patent/NO975703L/no
Publication of NO309088B1 publication Critical patent/NO309088B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO975703A 1995-06-07 1997-12-05 Alkylaminderivater av substituerte kinoksalin-2,3-dioner, farmasøytiske preparater omfattende forbindelsene, samt anvendelse av forbindelsene NO309088B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/474,876 US5654303A (en) 1995-06-07 1995-06-07 Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
PCT/US1996/006818 WO1996040651A1 (en) 1995-06-07 1996-05-13 Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Publications (3)

Publication Number Publication Date
NO975703D0 NO975703D0 (no) 1997-12-05
NO975703L true NO975703L (no) 1997-12-05
NO309088B1 NO309088B1 (no) 2000-12-11

Family

ID=23885301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975703A NO309088B1 (no) 1995-06-07 1997-12-05 Alkylaminderivater av substituerte kinoksalin-2,3-dioner, farmasøytiske preparater omfattende forbindelsene, samt anvendelse av forbindelsene

Country Status (24)

Country Link
US (1) US5654303A (no)
EP (1) EP0837854B1 (no)
JP (1) JPH11506725A (no)
KR (1) KR19990022481A (no)
AT (1) ATE229512T1 (no)
AU (1) AU716156B2 (no)
BG (1) BG63462B1 (no)
CA (1) CA2219755A1 (no)
CZ (1) CZ290899B6 (no)
DE (1) DE69625361T2 (no)
DK (1) DK0837854T3 (no)
EA (1) EA000762B1 (no)
EE (1) EE03683B1 (no)
ES (1) ES2187650T3 (no)
HU (2) HUP9900883A3 (no)
MX (1) MX9708431A (no)
NO (1) NO309088B1 (no)
NZ (1) NZ308318A (no)
PL (1) PL186764B1 (no)
PT (1) PT837854E (no)
SK (1) SK283181B6 (no)
UA (1) UA48183C2 (no)
WO (1) WO1996040651A1 (no)
ZA (1) ZA964760B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0784054T3 (da) * 1994-09-27 2002-03-25 Yamanouchi Pharma Co Ltd 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister
US6191134B1 (en) 1996-06-05 2001-02-20 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
CN110642798B (zh) * 2019-11-10 2020-07-24 湖南科技学院 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法
KR20260002803A (ko) * 2023-05-02 2026-01-06 지위, 엘엘씨 치료적 사용을 위한 암브록솔의 변형된 형태

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) * 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
JPH05117276A (ja) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd 新規な３環性キノキサリンジオン誘導体
JPH06228112A (ja) * 1993-02-05 1994-08-16 Yamanouchi Pharmaceut Co Ltd （１ｈ，４ｈ）キノキサリン誘導体
TW260660B (no) * 1993-04-22 1995-10-21 Sumitomo Pharma
WO1994026747A1 (en) * 1993-05-13 1994-11-24 Neurosearch A/S Ampa antagonists and a method of treatment therewith
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

Also Published As

Publication number Publication date
NO309088B1 (no) 2000-12-11
PL323824A1 (en) 1998-04-27
NZ308318A (en) 2001-04-27
AU716156B2 (en) 2000-02-17
US5654303A (en) 1997-08-05
CA2219755A1 (en) 1996-12-19
JPH11506725A (ja) 1999-06-15
DK0837854T3 (da) 2003-03-31
BG63462B1 (bg) 2002-02-28
SK169097A3 (en) 1998-07-08
UA48183C2 (uk) 2002-08-15
NO975703D0 (no) 1997-12-05
HUP9900883A2 (hu) 1999-09-28
SK283181B6 (sk) 2003-03-04
WO1996040651A1 (en) 1996-12-19
BG102079A (en) 1998-11-30
EA000762B1 (ru) 2000-04-24
PT837854E (pt) 2003-03-31
CZ387297A3 (cs) 1998-05-13
EP0837854B1 (en) 2002-12-11
ATE229512T1 (de) 2002-12-15
EE9700338A (et) 1998-06-15
AU5792096A (en) 1996-12-30
PL186764B1 (pl) 2004-02-27
DE69625361D1 (de) 2003-01-23
EP0837854A1 (en) 1998-04-29
HUP9900883A3 (en) 2001-02-28
HUP9802568A3 (en) 2000-01-28
EE03683B1 (et) 2002-04-15
ZA964760B (en) 1997-01-08
KR19990022481A (ko) 1999-03-25
ES2187650T3 (es) 2003-06-16
EA199800008A1 (ru) 1998-06-25
MX9708431A (es) 1998-02-28
CZ290899B6 (cs) 2002-11-13
DE69625361T2 (de) 2003-04-17
HUP9802568A2 (hu) 1999-03-29

Similar Documents

Publication Publication Date Title
NO975701D0 (no) Aminosyrederivater av substituerte kinoksalin-2,3-dion-derivater som glutamatreseptor-antagonister
NO975703D0 (no) Alkylaminderivater av substituerte kinoksalin-2,3-dioner som glutamatreseptor-antagonister
GT200200084A (es) Sales tartrato de 5, 8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno ycomposicionesfarmaceuticas de las mismas
WO2003103663A3 (en) Substituted pyrrolines as kinase inhibitors
HN1997000098A (es) Ccompuesto de indol 2, 3 sustituido como agentes antiinflamatorios y analgesicos.
ATE271120T1 (de) Freisetzungssystem
GT200300241A (es) Benzoxazinonas sustituidas y usos de las mismas
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
DK0830348T3 (da) Cycliske amin-derivater af substituerede quinoxalin-2,3-dioner som glutamatreceptorantagonister
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
EP1534284A4 (en) AMINO-SUBSTITUTED SULPHONANILIDES AND THEIR DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
ATE267600T1 (de) Mikroemulsionen zur transdermalen verabreichung von apomorphin für die behandlung von morbus parkinson
FR2742759B1 (fr) Glucuronyl-arabinarates, leur procede d'obtention et applications de ces produits
FI960051A0 (fi) Difluoristatonianalogeja
MXPA04003215A (es) Derivados de triazapina como agentes neurotroficos.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees